CTRI/2009/091/000282已完成2 期
A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, with an extended open-label inhaled corticosteroid period, in steroid-free, mild to moderate persistent asthma patients
ovartis Healthcare Pvt Ltd0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Mild to moderate asthma for at least 6 months.
排除标准
- •Past or recent history of significant medical illness and/or lab abnormalities including but not limited to ECG abnomalities, abnormal LFT, HIV, Hep B/C, allergic disorders, pancreatic disease, serious underlying respiratory diseases, life threatning asthma, renal disease etc
- •Surgical and/or medical conditions which significantly effect ADME of the drug.
- •Prior use of asthma medications (except SABA's) prior to 2 weeks of dosing
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, with an extended open-label inhaled corticosteroid period, in steroid-free, mild to moderate persistent asthma patientsEUCTR2008-005168-15-DEovartis Pharma Services AG50
招募中
不适用
A randomized, double-blind, two-way cross-over study to determine the effects of levetiracetam on corticospinal excitability in patients with treatment-controlled epilepsy, as measured by single and paired pulse TMS-EMG and TMS-EEG10039911EpilepsyNL-OMON49353Centre for Human Drug Research32
已完成
不适用
A randomized, double blind, two-way crossover clinical trial to evaluate of pharmacokinetic profiles of lacosamide in Korean subjectsKCT0003959Dong-A University Hospital48
进行中（未招募）
不适用
A double-blind, randomized, 2-way cross-over, phase II, efficacy trial in cancer patients to assess the overall efficacy, patient preference, morphine related side effect profile and safety of the Egalet® controlled release morphine formulation 30-240 mg once daily compared to MST Continus® 15-120 mg twice daily after 2 weeks of treatmentcancer patientsMedDRA version: 8.1Level: LLTClassification code 10058019Term: Cancer painEUCTR2006-006579-19-LTEgalet a/s60
进行中（未招募）
不适用
Effect of SBO-635 on mouth healthHalitosisOral HealthISRCTN10220812Innovation Labo Research42